

**Table: Epidemiologic studies on the risk of infection and severity of disease progression of COVID-19 with ACE inhibitors and angiotensin II receptor blockers**

Author Typ of study Period of time Country	Patients		Number of patients treated with ACE inhibitors / AT II blockers		Results adjusted Odds Ratio <sup>a</sup> (OR) (95% confidence interval)		Annotations
	Number of patients tested (T), infected (I) or with severe disease (S) or number of controls (C)		ACE	AT	ACE	AT	
<b>MANCIA</b> <sup>1</sup> Case-control study 21.2.20-11.3.20 Italy	I: 6.272 C: 30.759 S: 617 C: 2.969		I: 1.502 C: 6.569 S: n.s. C: n.s.	1.394 5.910 n.s. n.s.	<b>Infektion</b> 0,96 (0,87 - 1,07) <b>Severe disease</b> 0,91 (0,69 - 1,21)	0,95 (0,86 - 1,05) 0,83 (0,63 - 1,10)	Use of the antihypertensives in 2019, severe disease = ventilation or death
<b>REYNOLDS</b> <sup>2</sup> Cohort study 1.3.20-15.4.20 USA (New York)	T: 12.594 I: 5.894 S: 1.002		T: 1.044 I: 627 S: 150	1.328 664 162	<b>Positive test</b> (median difference) -2,5% (-6,7 - 1,6) <b>Severe disease</b> (median difference) -1,9% (-6,6 - 2,8)	2,2% (-1,9 - 6,3) -1,4% (-6,1 - 3,3)	Use of the antihypertensives in the last 18 months, severe disease = intensive care unit, ventilation or death
<b>MEHTA</b> <sup>3</sup> Cohort study 8.3.20-12.4.20 USA (Florida, Ohio)	T: 18.472 I: 1.735 S: 421		T: 1.322 I: 116 S: n.s.	982 98 n.s.	<b>Positive test</b> 0,89 (0,72 - 1,10) <b>Severe disease</b> 1,84 (1,22 - 2,79) <sup>b</sup>	1,09 (0,87 - 1,37) 1,61 (-1,04 - 2,50) <sup>b</sup>	Use of the antihypertensives at time of testing, severe disease = hospitalisation <sup>b</sup>
<b>MEHRA</b> <sup>4d</sup> Cohort study 20.12.19-28.3.20 Europe (65%), Asia, North Amerika	I: 8.910 S: 515		I: 770 S: 16	556 38	<b>Severe disease</b> 0,33 (0,20 - 0,54)	1,23 (0,87 - 1,74)	Infected hospitalised patients, Use of the antihypertensives at the time of hospitalisation, severe disease = in-hospital death
<b>De ABAJO</b> <sup>5</sup> Case-control study 1.3.20-24.3.20 Spain	S: 1.139 C: 11.390		S: 240 C: 2.192	237 1.552	<b>Severe disease</b> 0,80 (0,64 - 1,00) <sup>c</sup>	1,10 (0,88 - 1,37) <sup>c</sup>	Infected hospitalised patients, Use of the antihypertensives until at least 1 month prior to hospitalisation, severe disease = hospitalisation <sup>c</sup>

Abbreviations: n.s. = not stated

a In REYNOLDS median difference with 95% confidence interval is given.

b For the endpoint intensive care unit (161 patients) OR 1,77 (1,07 - 2,92 [ACE]), OR 1,16 (0,67 - 2,02 [AT]), respectively.

c For the endpoint intensive care unit or death (393 cases) OR 0,92 (0,65 - 1,29 [ACE]), OR 1,25 (0,89 - 1,77 [AT]), respectively.

d Study retracted, see below